Literature DB >> 33635005

Hindering triple negative breast cancer progression by targeting endogenous interleukin-30 requires IFNγ signaling.

Carlo Sorrentino1,2, Stefania Livia Ciummo1,2, Luigi D'Antonio1,2, Paola Lanuti1, Scott I Abrams3, Zhinan Yin4, Li-Fan Lu5, Emma Di Carlo1,2.   

Abstract

IL30mRNA expression is associated with the TNBC subtype. IL30 boosts proliferation and migration of TNBC cells and reshapes their immunity gene expression profile. The lack of endogenous IL30 hinders TNBC growth and progression and prolongs host survival. TNBC growth inhibition, due to the lack of endogenous IL30, requires INFγ production by T and NK cells.
© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Entities:  

Keywords:  IFNγ; interleukin-30; triple negative breast cancer; tumor microenvironment

Mesh：

Substances：

Year:  2021        PMID： 33635005      PMCID： PMC7828256          DOI： 10.1002/ctm2.278

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN： 2001-1326


  12 in total

1.  Involvement of chemokine receptors in breast cancer metastasis.

Authors:  A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

Review 2.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

3.  Interleukin-30 Promotes Breast Cancer Growth and Progression.

Authors:  Irma Airoldi; Claudia Cocco; Carlo Sorrentino; Domenico Angelucci; Serena Di Meo; Lamberto Manzoli; Silvia Esposito; Domenico Ribatti; Maria Bertolotto; Laura Iezzi; Clara Natoli; Emma Di Carlo
Journal:  Cancer Res       Date:  2016-08-22       Impact factor: 12.701

4.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.

Authors:  Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

5.  An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer.

Authors:  Christoph Garbers; Björn Spudy; Samadhi Aparicio-Siegmund; Georg H Waetzig; Jan Sommer; Christoph Hölscher; Stefan Rose-John; Joachim Grötzinger; Inken Lorenzen; Jürgen Scheller
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

6.  Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization.

Authors:  Carlo Sorrentino; Stefania L Ciummo; Giuseppe Cipollone; Sara Caputo; Matteo Bellone; Emma Di Carlo
Journal:  Cancer Res       Date:  2018-02-27       Impact factor: 12.701

7.  High susceptibility to liver injury in IL-27 p28 conditional knockout mice involves intrinsic interferon-γ dysregulation of CD4+ T cells.

Authors:  Song Zhang; Ruifang Liang; Wei Luo; Chang Liu; Xiaoli Wu; Yanan Gao; Jianlei Hao; Guangchao Cao; Xi Chen; Jun Wei; Siyuan Xia; Zheng Li; Ti Wen; Yunyun Wu; Xinglong Zhou; Puyue Wang; Liqing Zhao; Zhengzhou Wu; Sidong Xiong; Xiaoming Gao; Xiang Gao; Yongyan Chen; Qing Ge; Zhigang Tian; Zhinan Yin
Journal:  Hepatology       Date:  2013-02-12       Impact factor: 17.425

8.  Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage.

Authors:  Serena Di Meo; Irma Airoldi; Carlo Sorrentino; Alessia Zorzoli; Silvia Esposito; Emma Di Carlo
Journal:  Clin Cancer Res       Date:  2013-11-25       Impact factor: 12.531

9.  Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.

Authors:  Carlo Sorrentino; Zhinan Yin; Stefania Ciummo; Paola Lanuti; Li-Fan Lu; Marco Marchisio; Matteo Bellone; Emma Di Carlo
Journal:  J Immunother Cancer       Date:  2019-07-31       Impact factor: 13.751

10.  Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.

Authors:  Giovanna Ferrari-Amorotti; Claudia Chiodoni; Fei Shen; Sara Cattelani; Angela Rachele Soliera; Gloria Manzotti; Giulia Grisendi; Massimo Dominici; Francesco Rivasi; Mario Paolo Colombo; Alessandro Fatatis; Bruno Calabretta
Journal:  Neoplasia       Date:  2014-12       Impact factor: 5.715
View more
  2 in total

1.  Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome.

Authors:  Carlo Sorrentino; Stefania Livia Ciummo; Luigi D'Antonio; Cristiano Fieni; Paola Lanuti; Alice Turdo; Matilde Todaro; Emma Di Carlo
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 12.469

2.  CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.

Authors:  Carlo Sorrentino; Luigi D'Antonio; Stefania Livia Ciummo; Cristiano Fieni; Lorena Landuzzi; Francesca Ruzzi; Simone Vespa; Paola Lanuti; Lavinia Vittoria Lotti; Pier Luigi Lollini; Emma Di Carlo
Journal:  J Hematol Oncol       Date:  2022-10-13       Impact factor: 23.168
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.